US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Infertility · Ovarian Cancer · NWBO
NORTHWEST BIOTHERAPEUTICS
NORTHWEST BIOTHERAPEUTICS INC
NORTHWEST BIOTHERAPEUTICS drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4800 Montgomery Lane, Suite 800, Bethesda, MD 28014, US HQ
1998 Founded
20 Employees
Public company Type
NWBO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4800 Montgomery Lane, Suite 800, Bethesda, MD 28014, US
- Founded
- 1998
- Employees
- 20
- Programs
- 33
- Drugs
- 40
- Patents
- 595
NORTHWEST BIOTHERAPEUTICS pipeline
Portfolio lens on 40 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NORTHWEST BIOTHERAPEUTICS drug portfolio — 40 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
atosiban
Genito-urinary system and sex hormones (G02)Genito-urinary system and sex hormones (G02) compound in NORTHWEST BIOTHERAPEUTICS's portfolio. Molecular target: Oxytocin receptor.
- Target
- Oxytocin receptor
- Mechanism
- Oxytocin receptor antagonist
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
cetrorelix
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in NORTHWEST BIOTHERAPEUTICS's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in NORTHWEST BIOTHERAPEUTICS's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in NORTHWEST BIOTHERAPEUTICS's portfolio.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
US regulatory status: approved. Molecular target: Glycogen synthase kinase-3.
- Target
- Glycogen synthase kinase-3
- Mechanism
- Glycogen synthase kinase-3 inhibitor
-
US regulatory status: approved. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
mifepristone
Nervous system (NOT)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Progesterone receptor antagonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
panitumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
sotorasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.
-
Development asset linked to NORTHWEST BIOTHERAPEUTICS in public FDA and regional records.